MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$1,313,203
Unit: Dollar
Positive Cash Flow Breakdown
    • Accrued expenses
    • Stock-based compensation
    • Amortization of loan commitment ...
Negative Cash Flow Breakdown
    • Net loss
    • Accounts payable
    • Grant receivable
    • Prepaid expenses
Cash Flow
2025-12-31
2025-09-30
2025-06-30
Net loss
-1,999,397
-2,158,354
-8,484,763
Stock-based compensation
198,530
237,644
1,446,824
Amortization of loan commitment fee
17,439
17,440
382,014
Grant receivable
-46,958
63,393
-73,218
Prepaid expenses
4,642
-90,668
-152,351
Accounts payable
-52,677
383,364
67,749
Accrued expenses
574,502
92,769
159,356
Net cash used in operating activities
-1,313,203
-1,273,076
-6,349,687
Proceeds from issuance of common stock
-
-
15,000,000
Payment of financing/offering costs
-
-
116,664
Net cash provided by (used in) financing activities
-
-
14,883,336
Net (decrease) increase in cash
-1,313,203
-1,273,076
8,533,649
Cash and cash equivalents at beginning of period
10,354,773
11,627,849
3,094,200
Cash and cash equivalents at end of period
9,041,570
10,354,773
11,627,849
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net (decrease)increase in cash-$1,313,203 Accrued expenses$574,502 Stock-based compensation$198,530 Amortization of loancommitment fee$17,439 Net cash used inoperating activities-$1,313,203 Canceled cashflow$790,471 Net loss-$1,999,397 Accounts payable-$52,677 Grant receivable-$46,958 Prepaid expenses$4,642

Anebulo Pharmaceuticals, Inc. (ANEB)

Anebulo Pharmaceuticals, Inc. (ANEB)